Compare Globus Medical Inc. Class A Common Stock (GMED) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Invesco Preferred ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Invesco Preferred ETF trades at $9.93 (market cap $3.58B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.9× Invesco Preferred ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Invesco Preferred ETF for 96 Days on average.
| GMED | PGX | |
|---|---|---|
Market Cap | $10.25B | $3.58B |
Volume | 1,108,124 | 10,976,352 |
Sector | Health | — |
52-Week High | $96.82 | $11.61 |
52-Week Low | $58.33 | $9.95 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PGX trades at $9.98 with a modest 0.3% daily gain, though technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces significant resistance at $10, which also serves as multiple support levels. Recent corporate actions include scheduled dividends of $0.06 per share for H2-2026, providing income potential for shareholders.
The outlook remains cautious given the bearish technical setup and lack of available fundamental data. While dividend payments offer some investor appeal, the absence of key valuation metrics and financial ratios creates uncertainty about the company's underlying business performance and competitive positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
